Should I Get the RSV Vaccine While Pregnant?

When It Makes Sense

• Good fit: You are between 32 and 36 weeks pregnant during your local RSV season. Current CDC/ACIP guidance recommends one dose of RSV vaccine in this window so antibodies can pass to the baby before birth. This is most relevant if you expect to deliver during late fall, winter, or early spring, when RSV typically circulates most heavily, and you want to lower your newborn’s risk of severe lower-respiratory-tract disease in the first several months of life.
• Good fit: The infant preventive option, a monoclonal antibody called nirsevimab, is not expected to be available promptly after birth, or you prefer a single maternal injection over a separate newborn treatment. Maternal vaccination can be practical when prenatal care is reliable but follow-up pediatric access is uncertain, provided you meet the gestational-age and health criteria.

When You Should Avoid It

• Warning sign: You are outside the recommended 32–36 week window. If you are still in early or mid-pregnancy, the vaccine is not yet indicated and you should wait until the appropriate gestational age. If you are past 36 weeks, antibodies may not transfer in time to help before delivery, so infant nirsevimab after birth is usually the more suitable option. You should also pause if you have a history of severe allergic reaction to a prior RSV vaccine dose or a known allergy to a vaccine component, or if you are currently moderately or severely ill.
• Warning sign: Your baby is already planned to receive nirsevimab after birth, or your pediatrician or local public-health guidance recommends infant monoclonal antibody as the preferred preventive option. For most infants, authorities advise receiving either the maternal RSV vaccine or nirsevimab, not both, because they provide overlapping protection and one is generally sufficient.

Pros and Cons

Pros

• Infant protection during the highest-risk months. Antibodies passed across the placenta can help protect the baby from RSV from birth through roughly the first six months, which is the period when infants are most vulnerable to severe lower-respiratory-tract infection and hospitalization.
• One-step maternal option. A single injection given during a routine prenatal visit may be more convenient than arranging a separate newborn preventive treatment, especially if post-birth follow-up is unpredictable or you want protection in place at delivery.

Cons

• Strict timing and seasonal limits. The vaccine is designed for a narrow gestational window and RSV season, so people who learn about it too early, too late, or outside peak circulation may have limited benefit and may be better served by infant monoclonal antibody instead.
• Possible side effects and limited long-term data. Common reactions include soreness at the injection site, fatigue, headache, or muscle aches; serious allergic reactions are rare but possible. Because the vaccine for pregnant people is relatively new, ongoing monitoring continues, and individual risk profiles can differ.

Decision Checklist

• Am I currently between 32 and 36 weeks pregnant, and is this period within my local RSV season? If not, is infant nirsevimab a more appropriate option?
• Will my newborn have reliable access to nirsevimab after birth, and does my obstetric or pediatric provider recommend one prevention strategy over the other?
• Do I have any vaccine allergies, a history of severe reactions, current acute illness, or pregnancy complications that would change the risk-benefit balance?

Alternatives to Consider

The main alternative is infant RSV prevention with nirsevimab, a long-acting monoclonal antibody typically given to the baby shortly after birth or during the first week of life. In some high-risk or preterm infant situations, palivizumab may still be used according to local guidance. Non-medical measures also help reduce exposure: frequent handwashing, limiting contact with sick people during the newborn period, avoiding tobacco smoke exposure, and supporting breastfeeding if it is an option. These steps do not replace vaccination or monoclonal antibody protection, but they add useful layers of defense.

Final Recommendation

For many pregnant people at 32–36 weeks gestation during RSV season, with no contraindications and no plan for infant nirsevimab, getting the RSV vaccine is a reasonable option that may protect the newborn during the highest-risk early months. It is generally not the right choice if you are outside the recommended window, have relevant allergies or acute illness, or your baby will receive the monoclonal antibody after birth. The best next step is to discuss timing, local RSV activity, and the maternal-vaccine-versus-infant-antibody choice with your obstetric care provider. This guide is for informational purposes and is not a substitute for personalized medical advice.